A Study of the Effects of Amprenavir, a Protease Inhibitor, on Carbohydrate and Fat Metabolism in HIV-Infected Patients

Exclusion Criteria

• •Patients will not be eligible for this study if they:
• •Have taken both 3TC and stavudine (d4T).
• •Have taken a protease inhibitor (PI) or nonnucleoside reverse transcriptase inhibitor (NNRTI) for more than 7 days.
• •Have taken a PI within 60 days of study entry.
• •Have a history of diabetes.
• •Have a history of untreated gonad or thyroid disorder.
• •Have a stomach or intestinal disorder which may affect the way the body absorbs the study drugs, or which may make them unable to take medications by mouth.
• •Have received chemotherapy or radiation within 4 weeks prior to entry, or if they will need either of these during the study period.
• •Have lost or gained a significant amount of weight (greater than 5%) within the past 2 months.
• •Have a serious medical condition, such as heart disease.
• •Are allergic to any of the study drugs.
• •Have been treated for an infection or other medical illness within 14 days prior to study entry.
• •Have had a fever (over 38.5 degrees Celsius) for any 7 days or chronic diarrhea (more than 3 liquid stools per day for 15 days) within 30 days prior to study entry.
• •Have an AIDS-related cancer (other than Kaposi's sarcoma).
• •Abuse alcohol or drugs.
• •Have received certain medications.
• •Are pregnant.